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Background: The human retroviruses HIV-1 and HTLV-1 share the routes of infection with
hepatitis  viruses B and C. Co-infection by these agents are a common event, but we have
scarce  knowledge on co-infection by two or more of these agents.
Objective:  To evaluate the characteristics and risk factors for co-infections by HBV and HCV
in  patients infected by HIV-1 or/and HTLV-1, in Salvador, Brazil.
Methods:  In a case–control study we evaluated patients followed in the AIDS and HTLV clinics
of Federal University of Bahia Hospital. Clinical and epidemiological characteristics were
reviewed,  and patients were tested for the presence of serological markers of HBV and HCV
infections.  HCV-infected patients were  tested by PCR to evaluate the presence of viremia.
Results: A total of 200 HIV-1, 213 HTLV-1-infected, and 38 HIV-HTLV-co-infected individuals
were  included. HIV-infected patients were more likely to have had more  sexual partners
in  the lifetime than other patients’ groups. HIV-HTLV-co-infected subjects were  predomi-
nantly  male. Patients infected by HTLV or co-infected had a signiﬁcantly higher frequency of
previous syphilis or gonorrhea, while HIV infection was mainly associated with HPV infec-
tion. Co-infection was signiﬁcantly associated to intravenous drug use (IVDU). HBV and/or
HCV  markers were more frequently found among co-infected patients. HBV markers were
more  frequently detected among HIV-infected patients, while HCV was clearly associated
with  IVDU across all groups. AgHBs was strongly associated with co-infection by HIV-HTLV
(OR  = 22.03, 95% CI: 2.69–469.7), as well as conﬁrmed HCV infection (p = 0.001). Concomitant
HCV  and HBV infection was also associated with retroviral co-infection. Patients infected
by  HTLV-1 had a lower chance of detectable HCV viremia (OR = 0.04, 95% CI: 0.002–0.85).
Conclusions:  Infection by HCV and/or HBV is frequent among patients presenting retroviralinfection,  but risk factors and prevalence for each infection are distinct for each agent.
Retroviral  co-infection increases the risk of a positive AgHBs, but HTLV-1 infection seems to
increase the likelihood of HCV spontaneous clearance.
©  2013 Published by Elsevier Editora Ltda.
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Introduction
Viral hepatitis are important health problems worldwide.1–4
It is well known that simultaneous infection by HIV-1 and
the  viruses of hepatitis B or C can modify the outcomes of
such  infections, with a higher likelihood of chronic liver dis-
ease,  and a greater risk of rapid evolution to liver ﬁbrosis.5 The
introduction  of highly active antiretroviral therapy as standard
of  care for AIDS treatment increased the life expectancy of
HIV-1-infected patients, and chronic liver disease became a
common ﬁnding and a leading cause of death among co-
infected  patients.6,7
Although the natural history of co-infection by HIV-1 and
viral  hepatitis B (HBV) and C (HCV) is well known, there
is  scarce data on the characteristics and clinical impact of
co-infection  by HBV or HCV and another human retrovirus,
the  human T-cell lymphotropic virus type-1 (HTLV-1). HTLV-
1  shares the same route of infection that are commonly
associated with HIV-1 infection.8 However, the biological char-
acteristics  of these viruses are quite distinct, making the
outcome  of co-infection by these agents unpredictable. In a
recent work, we  demonstrate that patients co-infected by HIV-
1, HTLV-1 and HCV had a lower chance to present liver ﬁbrosis
than  those co-infected only by HCV and HIV-1, suggesting a
potential protective role of HTLV-1.9 Since co-infection by HIV-
1 and HTLV-1 is a frequent ﬁnding is some areas of the world,
it  is important to evaluate the risk factors for simultaneous
infection by human retroviruses and HBV/HCV. Our goal in the
present  work was  to describe the epidemiological character-
istics  of patients co-infected by HIV-1, and/r HTLV-1, HCV and
HBV.
Methods
Study  design
This is a case–control study to compare the risk factors for
co-infection by viral hepatitis B (HBV) and C (HCV) among
Brazilian patients infected by HIV-1 (cases), HTLV-1, or both
retroviruses  (controls).
Patients  and  settings
HIV-infected patients (case group): a total of 200 consecu-
tive  HIV-positive patients during their regular visit to clinical
follow-up  or laboratory evaluation entered the study. The
entry  criteria were:  a Western blot (WB) conﬁrmed infection
by  HIV-1, a negative serology for HTLV-1 and age ≥ 18 years.
HTLV-1 infected patients (control group 1): a total of 213 con-
secutive  patients were included in the study. WB  conﬁrmed
infection by HTLV-1, and a negative serology for HIV-1 and
age  ≥ 18 years.
HIV-1-HTLV-1 co-infected group (control group 2): a total of
38  HIV-infected patients (older than 18 years) with a simulta-
neous  positive serology for HTLV-1.All patients were  recruited in HIV or HTLV outpatients’
clinics of Federal University of Bahia Hospital, and provided
a  written informed consent to enter the study, which was
approved  by the institutional ethics review board (IRB). They 1 3;1  7(6):661–666
were  interviewed and had their medical charts reviewed to
collect  information on gender, age, sexual behavior (sexual
orientation, number of current/lifetime sexual partners, and
previous  history of sexually transmitted diseases), and illicit
drug  use.
Sample  size  calculation
Around 2500 HIV-infected patients are followed in our AIDS
clinic,  while the HTLV clinic cares for approximately 600
patients.  We  calculated the sample size to have a power of
80%  and a 95% conﬁdence interval (CI), by using an expected
prevalence of HBV equal to 5.5% for HIV-infected individuals
and  an infection rate similar to that found in general popula-
tion  (0.5%) for HTLV-infected subjects. This would require 197
patients in each group. For HCV, using the estimated rate of 3%
of infection for general population and 15% for HIV-infected
individuals we would need 167 patients in each group. For
co-infected  patients we  estimated a 40% prevalence of HCV
infection,  which would result in a sample of 23 patients in
this  group. For HBV infection, using an estimate of 25% preva-
lence  we would need 26 individuals to have the same power
and  CI. All co-infected cases under regular follow-up in our
clinics  were  included.
Laboratory  tests
Serological screening  for  HIV-1  and  HTLV-1
As a routine in our service, HIV infected patients are screened
by  enzyme immunoassays (EIA) for HTLV-1/2 antibodies
(Vironostika or Murex). Reactive samples are conﬁrmed by
a  Western blot (Wb) test, capable of discriminating between
HTLV-1  and HTLV-2 infections (Genelabs, Singapore). Similarly,
all  HTLV-1 patients are routinely screened for HIV-1 antibod-
ies  by EIA. HIV-1 infection conﬁrmation is made by Wb  or by
molecular  methods (viral load determination by NASBA until
2007  and b-DNA from 2007 to present). Screening tests for
both  retroviruses were  acquired from different licensed man-
ufacturers,  since the serological diagnosis for both infections
in  our study covered several years, and patients were eval-
uated  in different periods of time. All patients included in
the  study were asked to provide a blood sample for labora-
tory  tests. Plasma samples were stored at −20 ◦C until further
testing.
Hepatitis  B  (HBV)  and  C  (HCV)  infection
All patients were tested for markers of HBV infection (AgHBs
and  Anti-HBc serology) by EIA (Diasorin, Vercelli, Italy). Anti-
HCV  antibodies were  detected by EIA (Diasorin, Vercelli, Italy)
and  reactive samples were  conﬁrmed by RIBA (Chiron RIBA
HCV  3.0 Strip Immunoblot Assay). Detection of HCV in plasma
was  attempted by RT-PCR (EZ r Tth RNA PCR Kit, Applied
Biosystems) in a single step, using the primers of the non-
codifying region 5′ KY 78 CAC TCG CAA GCA TAT CAG GCA GT,
and  KY 80 GCA GAA AGC GTG TAG CCA TGG CG.
Patients presenting with HCV detectable viremia had their
genotypes  determined by TruGene sequencing system (TRU-
GENE  5′NC – Visible Genetics Toronto – Canadá – Bayer Health
Care  Diagnostics).
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Table 1 – Demographic characteristics of patients and risk factors for acquisition of retroviral infection, according to their
serological status for HIV and HTLV.
Variables Group 1 (HIV+)
n = 200
Group  2 (HTLV+)
n  = 213
Group 3 (HIV/HTLV+)
n  = 38
Mean age (SD) 39 (9.6) 49 (13) 43 (8.2)
Gender (%)
Male  54.5 46.6 62.5a
Female 45.5 53.4 37.5
Men/women ratio 1.2:1 1:1 1.6:1
Marital status (%)
Married  30.8 54.0  41.9
Divorced 8.6 9.4 0.0
Single 46.6 31.9 41.9
Widow 14.0 4.7 16.1
Sexual behavior
Heterosexual 68.7 96.7  81.3
Homosexual 15.7 0.5 9.4
Bisexual 15.7 2.8 9.4
Condom use
Always  1.0 1.9 0.0
Sometimes 47.5 19.2 56.3
Never 51.5 78.9 43.7
Number of sex partners
<10  49.7 75.9 65.5
>10 50.2 24.1 34.5
Sex partner with multiple partners 85.1a 42.6 66.7
Anal sex 56.4 ND 53.1
Commercial sex 15.5 ND 28.1
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tatistical  analysis
ur main outcomes of interest were  markers of risk expo-
ure  to HIV-1, HTLV-1 and HCV/HBV infections. We calculated
revalence and 95% conﬁdence intervals (CI) based on bino-
ial  distributions. Summary statistics included frequency
ables  for categorical variables, medians and interquartile
ange (IQRs) for continuous variables. We  conducted univari-
te  analyses examining associations between groups using
he  chi-square test, or Fisher’s exact test (when appropriate),
nd  calculated odds ratios (ORs) and 95% conﬁdence intervals
CI).  To further examine associations in subgroups of interest,
n  particular between risk factors for different infections, we
onducted  stratiﬁed analyses.
esults
emographics  and  risk  behavior  for  acquisition  of
nfections
he mean age was  similar for the three groups, but patients in
o-infected (HIV-HTLV) group were  signiﬁcantly more  likely to
e male (p = 0.001, Yates corrected). Although it did not reach
tatistical  signiﬁcance, we observed a higher frequency (31%)
f  men  reporting sex with other men  (MSM)  in group 1, than in
roup 2 (3%) or group 3 (19%). The use of condoms was  seldom
eported:  almost all patients (98%) in the 3 groups declared notto  use condoms during sexual intercourse. A signiﬁcant differ-
ence  was  detected in the number of sexual partners (lifetime)
across  the groups: 50% of patients in group 1 (HIV-1-infected)
reported more  than 10 sexual partners, in comparison with
24%  of those in group 2 (HTLV-1 infection), and 34.5% in group
3  (p < 0.001 for comparison between group 1 and groups 2 or
3).  On the other hand, a signiﬁcant difference (p < 0.01) was
found  in the frequency of illicit drug use (IDU), with patients
in  Group 1 (16.2%), and Group 2 (3%) reporting a signiﬁcantly
lower frequency of IDU, in comparison with those in Group 3
(32%, p < 0.01, Yates corrected). Table 1 shows the main char-
acteristics  of the patients involved in the study. In addition,
signiﬁcantly more  patients in group 1 reported IVDU as sexual
partners,  compared with only 8% of those in group 2 (p = 0.001,
Yates  corrected). Among co-infected patients, 32% declared
themselves to be illicit drug users (90% IV), and 46% had an
IVDU  sexual partner (p = 0.001 compared with group 2). The
history  of previous use of blood or blood products was  not sig-
niﬁcantly  different in group 1 (8%), group 2 (19%) and group 3
(15%). The frequency of patients who were breastfed was  sim-
ilar  in groups 2 (88%) and 3 (98%). For group 1, this information
was  unavailable.
History of a previous sexually transmitted disease (STD)
was  signiﬁcantly more  frequent (p < 0.001, Yates corrected) for
patients in group 3 (58%) than for those in group 2 (27%) or
group  1 (37%). The frequency of speciﬁc STDs was also differ-
ent  for each group. Group 1 were more  likely to have a previous
history  of HPV (30%) than groups 2 (17%) or 3 (23%, p < 0.001,
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Table 2 – Frequency of previous sexually transmitted diseases (STD) among the studied groups of patients.
Group 1 (HIV+)
n  (%)
Group  2 (HTLV+)
n  (%)
Group 3
(HIV/HTLV+)
n  (%)
STD 73/200 (36.6) 36/132 (27.3) 22/38 (57.8)a
Gonorrhea 26/73 (35.0) 33/36 (92.4)a 11/22 (50.0)
Syphilis 17/73 (23.2) 9/36 (25.0)b 11/22 (50.0)b
HPV 22/73 (30.0)a 2/36 (5.5) 4/22 (18.1)
Genital Herpes 19/73 (26.0) 6/36 (16.6) 5/22 (22.7)
a p < 0.001 for comparison with the other 2 groups.
b p < 0.001 for comparison with group 1.
Table 3 – Prevalence of serological markers for viral hepatitis B and C.
Markers Group 1 (HIV+)
n  = 200, n (%)
Group  2 (HTLV+)
n = 213, n (%)
Group 3
(HIV/HTLV+)
n = 38, n (%)
HBsAg 1 (0.5) 5 (2.3) 8 (21.0)
Anti-HBC 43 (21.5) 40 (18.8) 18 (47.3)
Hepatitis B 44 (22.0) 41 (19.2) 25 (65.7)a
Hepatitis C 26 (13.0) 9 (4.2) 13 (34.2)a
Hepatitis B and C 11 (5.5) 3 (1.4) 9 (23.6)a
Our results demonstrated that, although HIV-1, HTLV-1, HCV,
and  HBV share some common routes of infection, the risks for
Table 4 – Frequency of HCV subtypes among selected
patients.a
HCV subtype Frequency (%)
1a 13 (28.9)
1b  15 (33.3)
2b  1 (2.2)
3a  12 (26.7)
3d  3 (6.7)
4a  1 (2.2)a p < 0.001 for comparison between group 3 and the other 2 groups.
Yates corrected), while group 2 reported more  gonorrhea (92%)
and  syphilis (25%), and group 3 reported a higher frequency
of  syphilis (50%) than the other 2 groups (p < 0.001 for all cal-
culations).  Table 2 shows the frequency of each STD for the
different  groups of patients.
Prevalence  of  HBV  and  HCV  markers
The overall frequency of serological markers for previous
HBV  infection (HBsAg and/or Anti-HBc) was  27.5% (55/200)
in  Group 1, 20.6% (44/213) in Group 2, and 89.5% (34/38) in
Group  3 (p = 0.001, Yates corrected). The prevalence of HBV
surface  antigen (HBsAg) was  lower (0.5%) among HIV singly
infected,  and among HTLV-1-infected patients (2.5%), than in
patients co-infected by both retroviruses (21.0%, OR = 22.03,
95%  CI: 2.69–469.7, p = 0.0002, Yates corrected). The preva-
lence  of anti-HCV (RIBA conﬁrmed) was  also higher among
co-infected patients (28.9%), than in patients infected by HIV-1
alone  (10.5%), or HTLV-1 alone (4.2%, p = 0.001, Yates corrected).
In  addition, evidence of previous infections by both, HCV and
HBV  was  also higher in the co-infected group (23.6%) than
in  singly infected by HIV-1 (5.5%) or HTLV-1 (1.4%, p < 0.001,
Yates  corrected) groups. Table 3 summarizes the serological
evidence for these infections.
The risk factors associated with HCV and HBV infections
were  distinct for each group of patients: individuals with a
positive  marker for HBV were  more  likely to be male and
infected  by HIV-1 (70.5%), or co-infected by HIV-1 and HTLV-
1  (78.0%), than HTLV-1-singly infected ones (58.5%, p < 0.001,
Yates  corrected). In addition, patients infected by HIV-1 were
more  likely to be homo-bisexual than those infected by HTLV-1
alone  (p < 0.001, Yates corrected). HCV infection was basically
associated with IVDU, for all groups of patients (p < 0.01, Yates
corrected,  for all comparisons between groups).The prevalence of detectable HCV RNA plasma viremia was
compared  in the three groups. Among patients with a RIBA-
conﬁrmed  HCV infection, detectable HCV viremia was  present
in  17/17 (100%) samples tested among HIV-1 singly infected
patients,  in 4/7 (57.1%) of HTLV-1-infected patients, and in
8/11  (72.7%) of HIV-HTLV co-infected patients. Patients singly
infected  by HTLV-1 had a signiﬁcantly lower likelihood of hav-
ing  detectable HCV viremia, in comparison with those infected
by  HIV-1 alone (singly or co-infected with HTLV-1, OR = 0.04,
95%  CI: 0.002–0.85).
The  distribution of HCV subtypes is presented in Table 4.
We  did not detect any association between speciﬁc HCV sub-
types  and co-infections, but there was  a trend for higher
frequency of subtype 1a among IVDU patients (Table 5).
DiscussionTotal 45 (100.0)
a Includes all patients with an available subtype determination.
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Table 5 – Demographic characteristics and risk factors for HCV infection according to HCV subtype.
Characteristics HCV subtype Total p-Valueb
1a 1b 2b 3a 3d 4a
Age/years
18–30 2  (18.2)a – – 1 (8.3) – – 3 (7.3)
31–40  2 (18.2) 3 (23.1) 1 (100.0) 1 (8.3) 1 (33.3) – 8 (19.5)
41–50  6 (54.5) 8 (61.5) – 7 (58.3) 1 (33.3) 1 (100.0) 23 (56.1)
>50  1 (9.1) 2 (15.4) – 3 (25.0) 1 (33.3) – 7 (17.1)
Total  11 (100.0) 13 (100.0) 1 (100.0) 12 (100.0) 3 (100.0) 1 (100.0) 41 (100.0) 0.60
Gender
Male 9 (69.2) 10 (66.7) 1 (100.0) 7 (58.3) 1 (33.3) 1 (100.0) 29 (64.4)
Female 4 (30.8) 5 (33.3) – 5 (41.7) 2 (66.7) – 16 (35.6)
Total  13 (100.0) 15 (100.0) 1 (100.0) 12 (100.0) 3 (100.0) 1 (100.0) 45 (100.0) 0.68
Blood transfusion
Yes  1 (14.3) 1 (8.3) 1 (100.0) 1 (10.0) – – 4 (12.1)
No  6 (85.7) 11 (91.7) – 9 (90.0) 3 (100.0) – 29 (87.9)
Total  7 (100.0) 12 (100.0) 1 (100.0) 10 (100.0) 3 (100.0) – 33 (100.0) 0.92
Sexual behavior
Heterosexual 7 (100.0) 10 (76.9) 1 (100.0) 6 (60.0) 2 (66.7) – 26 (76.5)
Homosexual – 1 (7.7) – 1 (10.0) 1 (33.3) – 3 (8.8)
Bisexual – 2 (15.4) – 3 (30.0) – – 5 (14.7)
Total  7 (100.0) 13 (100.0) 1 (100.0) 10 (100.0) 3 (100.0) – 34 (100.0) 0.42
IV drug use
Yes  6 (75.0) 3 (23.1) – 5 (50.0) – – 14 (40.0)
No  2 (25.0) 10 (76.9) 1 (100.0) 5 (50.0) 3 (100.0) – 21 (60.0)
Total  8 (100.0) 13 (100.0) 1 (100.0) 10 (100.0) 3 (100.0) – 35 (100.0) 0.052
a Number of patients (%).
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cquiring these agents are quite distinct. HIV-1, as expected,
as  associated with a higher number of sexual partners, a
igher  likelihood of being male, homosexual, having an IVDU
exual  partner, and having a higher number of sexual part-
ers.  Co-infection by HIV-1 and HTLV-1 was  clearly associated
ith  use of illicit drugs, especially by IV route, and with having
VDU  as sexual partners. For group 2 (HTLV-1 infected patients)
he  only detected risk was  a higher frequency of gonorrhea and
yphilis.
There  is clear association between a higher number of sex-
al  partners and increased risk for HIV-1 infection. In addition,
he  association of sexual contact with IVDU and HIV-1 infec-
ion  was  also expected, since these patients usually present
 risky behavior, through sharing injection equipment, hav-
ng  commercial sex, or sexual relationships with other high
isk  individuals.10,11 The detected linkage between speciﬁc
TDs  and HTLV-1 infection suggest a higher sexual exposure
o  HTLV-1, which seems to be the preferential route of trans-
ission  for this speciﬁc group.
The viral hepatitis agents HBV and HCV were  much  more
revalent across the study groups than in general population.
vailable data show that HCV (1–2%) and HBV (0.3–1%) are less
requent  in the general population than that found in groups
 and 3.12–15 However, the prevalence of HBsAg (an evidence
f  persistent HBV infection), was  signiﬁcantly lower in HIV-
nfected  patients (0.5%) than in HTLV-1 (2.5%) or co-infected
atients (21%) groups. It suggests that infection by HTLV-1
an  reduce the spontaneous clearance of HBV, and this risk
ncreases  in the simultaneous presence of HIV-1 infection. InB and 4A were not included in the analysis due to its low frequency.
addition,  HIV-1-HTLV-1 co-infected patients were  also more
likely  (28.9%) to be also infected by HCV, than HIV-1 (10.5%)
or  HTLV-1 (4.2%) singly infected groups. Infection by both HBV
and  HCV were  also more  frequent in group 3, probably as a
reﬂex  of a higher prevalence of IVDU in this speciﬁc group.
The  variables associated with HBV infection were  being
male,  homo-bisexual, and infected by HIV-1. On the other
hand,  HCV infection was  basically associated with IVDU.
However, HCV spontaneous clearance was  signiﬁcantly less
frequent  for patients infected by HIV-1 than for those infected
by  HTLV-1 (singly or co-infected). This suggests that the
interactions between these hepatotropic viruses and the two
distinct  human retrorviruses can be diverse: while HBsAg
was  less frequently found in HIV-1 infected patients, HCV
viremia  was  more  frequent in this group. On the other hand,
co-infection by HTLV-1 seems to increase the spontaneous
clearance of HCV viremia, but was  associated with a higher
rate  of HBV antigenemia.
HTLV-1  infection has a controversial effect on HIV-1 infec-
tion  natural course. Although it seems evident that HTLV-2
do  not interfere in AIDS clinical course, several evidence of
laboratory  and clinical studies demonstrate that such inter-
action  can be deleterious for HIV-1 infection.16–18 However,
in  a recent study we found that HTLV-1 can modulate the
immune  response of HIV-HTLV co-infected patients with an
increase in the production of IL-2 and gamma-Interferon (Th1
type  response).19 This fact could favor the immune response
against HCV, which is largely dependent on endogenous pro-
duction  of interferon, providing the conditions for higher
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spontaneous clearance of HCV viremia. Our ﬁndings suggest
that  spontaneous HCV clearance is signiﬁcantly more  likely to
occur in HTLV-1 infected patients, probably as a consequence
of  such immune modulation. A previous work conducted by
our group had found similar results.9
On the other hand, the role of HIV-HTLV co-infection on
HBV  infection natural course is not well understood. As far as
we  could see, there is only a few epidemiological published
papers  on such co-infection, with low prevalence of simulta-
neous  infections, but no information on the potential effects
of  HTLV on HIV-HBV infection natural history.4,20–22 Other con-
founding  factor is the prevalence of simultaneous infection
by  all these four viral agents, in a limited number of patients,
making  difﬁcult to clarify the exact role of each virus on these
ﬁndings.
It  came as a surprise to detect higher frequency of HBsAg
in  HTLV-1, and among HIV-HTLV-infected patients. This fact
can suggest that HTLV-1 can negatively impact the HBV clear-
ance  (in contrast to that detected for HCV), and co-infection by
HIV-1 can even amplify this effect. Again, the main limitations
of  our conclusions are the small sample size, which makes it
difﬁcult to clearly identify potential confounders.
Simultaneous HIV-1 and HTLV-1 infections are frequently
detected in regions were  these agents are prevalent. HCV and
HBV  also share some routes of transmission, which makes
co-infection by all these agents quite a predictable ﬁnding,
especially among IVDU. It is important to be aware of these
potential  interactions between such agents, since they can
signiﬁcantly  affect the natural course of each of these viral
infections,  mostly for HIV-1 infected patients. Studies includ-
ing  a higher number of patients are necessary to better clarify
these  questions.
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